Amgen (AMGN) Competitors $293.92 +7.94 (+2.78%) As of 04/14/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock AMGN vs. GILD, VRTX, REGN, ALNY, BIIB, UTHR, INCY, BMRN, EXEL, and NBIXShould you be buying Amgen stock or one of its competitors? The main competitors of Amgen include Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), United Therapeutics (UTHR), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Exelixis (EXEL), and Neurocrine Biosciences (NBIX). These companies are all part of the "biotechnology" industry. Amgen vs. Gilead Sciences Vertex Pharmaceuticals Regeneron Pharmaceuticals Alnylam Pharmaceuticals Biogen United Therapeutics Incyte BioMarin Pharmaceutical Exelixis Neurocrine Biosciences Amgen (NASDAQ:AMGN) and Gilead Sciences (NASDAQ:GILD) are both large-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, community ranking, earnings, analyst recommendations, dividends, profitability, media sentiment, institutional ownership and valuation. Is AMGN or GILD more profitable? Amgen has a net margin of 12.24% compared to Gilead Sciences' net margin of 1.67%. Amgen's return on equity of 176.32% beat Gilead Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Amgen12.24% 176.32% 11.71% Gilead Sciences 1.67%31.63%10.38% Is AMGN or GILD a better dividend stock? Amgen pays an annual dividend of $9.52 per share and has a dividend yield of 3.2%. Gilead Sciences pays an annual dividend of $3.16 per share and has a dividend yield of 3.0%. Amgen pays out 126.1% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Gilead Sciences pays out 854.1% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Amgen has raised its dividend for 14 consecutive years. Amgen is clearly the better dividend stock, given its higher yield and longer track record of dividend growth. Does the media favor AMGN or GILD? In the previous week, Amgen had 42 more articles in the media than Gilead Sciences. MarketBeat recorded 76 mentions for Amgen and 34 mentions for Gilead Sciences. Gilead Sciences' average media sentiment score of 1.37 beat Amgen's score of 0.97 indicating that Gilead Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amgen 47 Very Positive mention(s) 3 Positive mention(s) 11 Neutral mention(s) 11 Negative mention(s) 1 Very Negative mention(s) Positive Gilead Sciences 27 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better earnings and valuation, AMGN or GILD? Amgen has higher revenue and earnings than Gilead Sciences. Amgen is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAmgen$33.42B4.73$4.09B$7.5538.93Gilead Sciences$28.75B4.61$480M$0.37287.84 Which has more risk & volatility, AMGN or GILD? Amgen has a beta of 0.59, meaning that its share price is 41% less volatile than the S&P 500. Comparatively, Gilead Sciences has a beta of 0.32, meaning that its share price is 68% less volatile than the S&P 500. Do insiders and institutionals have more ownership in AMGN or GILD? 76.5% of Amgen shares are held by institutional investors. Comparatively, 83.7% of Gilead Sciences shares are held by institutional investors. 0.7% of Amgen shares are held by insiders. Comparatively, 0.2% of Gilead Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Do analysts rate AMGN or GILD? Amgen currently has a consensus price target of $314.91, suggesting a potential upside of 7.14%. Gilead Sciences has a consensus price target of $105.12, suggesting a potential downside of 1.30%. Given Amgen's higher possible upside, equities research analysts clearly believe Amgen is more favorable than Gilead Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amgen 2 Sell rating(s) 9 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 2.48Gilead Sciences 0 Sell rating(s) 11 Hold rating(s) 15 Buy rating(s) 3 Strong Buy rating(s) 2.72 Does the MarketBeat Community favor AMGN or GILD? Gilead Sciences received 929 more outperform votes than Amgen when rated by MarketBeat users. Likewise, 76.87% of users gave Gilead Sciences an outperform vote while only 71.83% of users gave Amgen an outperform vote. CompanyUnderperformOutperformAmgenOutperform Votes155371.83% Underperform Votes60928.17% Gilead SciencesOutperform Votes248276.87% Underperform Votes74723.13% SummaryAmgen beats Gilead Sciences on 14 of the 22 factors compared between the two stocks. Remove Ads Get Amgen News Delivered to You Automatically Sign up to receive the latest news and ratings for AMGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AMGN vs. The Competition Export to ExcelMetricAmgenBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$158.03B$2.90B$5.35B$7.58BDividend Yield3.38%1.91%5.11%4.33%P/E Ratio38.9330.3721.7517.78Price / Sales4.73438.19380.5194.51Price / Cash9.98168.6838.1534.64Price / Book26.893.456.433.99Net Income$4.09B-$72.06M$3.20B$247.24M7 Day Performance4.87%8.60%9.08%8.29%1 Month Performance-6.31%-17.45%-6.04%-5.37%1 Year Performance10.70%-29.74%10.66%-0.24% Amgen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AMGNAmgen4.2679 of 5 stars$293.92+2.8%$314.91+7.1%+10.0%$158.03B$33.42B38.9325,200Analyst ForecastGILDGilead Sciences4.5341 of 5 stars$107.31+0.1%$105.12-2.0%+56.5%$132.89B$28.75B288.4517,000Positive NewsVRTXVertex Pharmaceuticals4.1048 of 5 stars$479.98+1.1%$509.17+6.1%+25.0%$122.86B$11.02B-217.476,100Short Interest ↓Analyst RevisionPositive NewsREGNRegeneron Pharmaceuticals4.8749 of 5 stars$578.87+0.9%$966.88+67.0%-36.9%$63.30B$14.20B15.1311,900Analyst ForecastPositive NewsALNYAlnylam Pharmaceuticals4.5031 of 5 stars$235.86+0.1%$316.25+34.1%+61.6%$30.49B$2.25B-108.002,000BIIBBiogen4.6979 of 5 stars$120.48-2.0%$213.33+77.1%-39.8%$17.63B$9.68B10.768,720UTHRUnited Therapeutics4.9044 of 5 stars$294.24+0.6%$388.25+32.0%+22.2%$13.18B$2.88B12.89980Positive NewsINCYIncyte4.8353 of 5 stars$60.92+0.6%$74.88+22.9%+10.0%$11.76B$4.24B225.082,320BMRNBioMarin Pharmaceutical4.8914 of 5 stars$59.38-1.5%$94.00+58.3%-35.3%$11.33B$2.85B26.993,401Gap UpEXELExelixis4.256 of 5 stars$34.88+0.9%$37.59+7.8%+56.7%$9.75B$2.17B19.681,220Positive NewsGap DownNBIXNeurocrine Biosciences4.8404 of 5 stars$93.22-2.5%$163.52+75.4%-29.5%$9.29B$2.36B28.311,200Analyst UpgradeNews CoveragePositive NewsGap Up Remove Ads Related Companies and Tools Related Companies GILD Competitors VRTX Competitors REGN Competitors ALNY Competitors BIIB Competitors UTHR Competitors INCY Competitors BMRN Competitors EXEL Competitors NBIX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AMGN) was last updated on 4/15/2025 by MarketBeat.com Staff From Our Partners[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amgen Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amgen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy AMGN Stock Free AMGN Stock Alerts